Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02866240 · ClinicalTrials.gov registry record · NA
Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy
A NA study, sponsored by Neuroelectrics Corporation.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02866240: Completed NA study, sponsored by Neuroelectrics Corporation.
NCT02866240 is a NA study that has completed, run by Neuroelectrics Corporation. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02866240, a NA study, has completed, sponsored by Neuroelectrics Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single site, non-randomized, prospective, open-label, interventional pilot/feasibility study. Patients recruited will have medically-refractory focal neocortical epilepsy, defined on the basis of presence of focal spikes and (if available) focal seizure onsets originating from the lateral cortical surface of any lobe. All patients and referring physicians will be requested to maintain their current antiepileptic drugs throughout the study with changes after enrollment permitted only to maintain pre-enrollment drug levels, or if clinically necessary. The primary outcome measure will be the change in seizure frequency (seizures/week) as compared to baseline. Patients with medically-refractory neocortical epilepsy will receive cathodal tDCS administered to the seizure focus for 10 sessions over a 2-week period with the allowance of make-up sessions in week three. Subjects will be evaluated at baseline, during the stimulation sessions, and 8 weeks after the completion of the tDCS visits
Primary Outcome
Seizure frequency relative to pre-treatment baseline
Interventions
- DEVICE Cathodal Transcranial Direct Current Stimulation (tDCS).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
What the finished NCT02866240 record still lists
NCT02866240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Cathodal Transcranial Direct Current Stimulation (tDCS). is the first listed.
NCT02866240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02866240 about?
NCT02866240 is a clinical study titled "Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy". This is a single site, non-randomized, prospective, open-label, interventional pilot/feasibility study. Patients recruited will have medically-refractory focal neocortical epilepsy, defined on the basis of presence of focal spikes and (if available) focal seizure onsets originating from the lateral ...
What is the current status of trial NCT02866240?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2017-09-21. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02866240?
The interventions under investigation include: Cathodal Transcranial Direct Current Stimulation (tDCS). (DEVICE).
Who is sponsoring clinical trial NCT02866240?
This trial is sponsored by Neuroelectrics Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02866240's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI